From Web3 to Healthcare: Why Our CSO Bet on Early Detection

Jin Matsumoto was building the future of digital ownership. At Animoca Brands, one of Asia's most influential Web3 companies, he helped shape ecosystems where people could truly own their digital assets—from virtual land in The Sandbox to gaming economies that rewarded real participation. The work was ambitious, global, and financially successful. By most measures, he had arrived.

Then came a question that wouldn't leave him alone: What are we really creating here?

The Value Question

Web3 and blockchain technology, at their core, solve a democratization problem. They remove intermediaries and put power—and ownership—directly into users' hands. Jin understood this deeply. He had spent years thinking about how to make financial systems more accessible, more transparent, more equitable on a global scale.

But sitting in meetings about digital assets and decentralized finance, Jin began to realize something. Financial value, no matter how fairly distributed, has limits. You can build wealth. You can lose it. You can transfer it.

Health data, on the other hand, is irreplaceable.

"In crypto and Web3, you create financial value. In healthcare, you create something that can't be undone—you give someone their life back. That realization changed everything for me."

The insight wasn't a rejection of Web3's mission. It was a reordering of priorities. If democratization was the principle Jin believed in—and it was—then there was no more critical domain to democratize than access to early health insights.

The Same Mission, Different Arena

When Jin discovered EYE TELL, the through-line became clear. Here was a technology built on the same democratization ethos that had driven his Web3 work, but applied to something more fundamental than digital ownership: the ability to detect disease early, before symptoms become serious.

EYE TELL's proposition is elegantly simple. The pupil contains measurable markers of systemic health—indicators of diabetes, hypertension, cardiac risk, neurological conditions, and mental health states. Those insights have always existed. But the infrastructure to access them has been locked behind expensive hardware, specialist training, and geography. A person in a rural area, or without immediate access to healthcare, couldn't benefit from this knowledge.

EYE TELL removes that lock. A 30-second pupil analysis through a smartphone browser. No specialized equipment. No travel to a clinic. Just data that tells you something true about your health, right now, accessible everywhere.

That's democratization applied to preventive medicine.

Why Early Detection Matters—The Strategic Insight

Jin's Web3 background taught him to think systemically about incentives and outcomes. In healthcare, the incentive structure is often misaligned: the system responds to disease, not prevention. Patients don't seek care until symptoms appear. By then, conditions have progressed, treatment is more complex, and costs multiply.

Early detection changes that equation. When someone learns—through a simple, accessible screening—that they have early-stage hypertension or uncontrolled diabetes, they can act immediately. They can seek proper care, adjust lifestyle, begin treatment before irreversible damage occurs. The action that early detection enables is not speculative; it's direct and measurable.

This is where Jin's strategic role as CSO focuses:

From Vision to Action

The career pivot from Web3 to healthcare isn't actually a pivot away from Jin's core values. It's a clarification. Both spaces are about removing barriers to access, about giving people information and agency they didn't have before.

In Web3, that meant financial self-sovereignty. In healthcare, it means health sovereignty—the ability to know your own health status without gatekeepers, geography, or cost standing in the way.

The question that started Jin's journey—"What are we really creating here?"—has its answer now. At EYE TELL, he's building infrastructure for prevention. He's helping create a world where a person can take 30 seconds, run a pupil analysis on their phone, learn something vital about their health, and take action before disease takes hold.

That's a kind of value creation that doesn't depreciate. It compounds. Every person who gets early detection is a person who can prevent complications, who stays healthier longer, who has more time with the people they love. You can't liquidate that on an exchange, and you don't need to.

It's the most valuable thing there is.